Concurrent Investment Advisors LLC Invests $944,000 in Bio-Rad Laboratories, Inc. $BIO

Concurrent Investment Advisors LLC acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 4th quarter, Holdings Channel.com reports. The fund acquired 3,116 shares of the medical research company’s stock, valued at approximately $944,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Quent Capital LLC acquired a new stake in shares of Bio-Rad Laboratories during the third quarter valued at $25,000. Farther Finance Advisors LLC raised its stake in Bio-Rad Laboratories by 52.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. Financial Management Professionals Inc. purchased a new position in Bio-Rad Laboratories in the 4th quarter valued at about $61,000. Finally, CWM LLC boosted its stake in shares of Bio-Rad Laboratories by 82.0% during the 3rd quarter. CWM LLC now owns 202 shares of the medical research company’s stock worth $57,000 after purchasing an additional 91 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories News Roundup

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Revenue/operational positives — Q1 revenue of $592.1M slightly beat the consensus (~$590M) and revenue was up ~1.1% year?over?year; the company still shows a strong net margin (~29%). These factors provide some support versus a pure earnings shock. MarketBeat Q1 Release
• Neutral Sentiment: Analyst action — Wells Fargo cut its price target from $320 to $290 but kept an “equal weight” rating; the new PT still implies upside versus the current share level, which moderates the negative read on the name. Benzinga
• Neutral Sentiment: Full earnings call transcript now available — details on segment drivers, margin commentary and near?term cadence are in the call and may clarify management’s guidance changes for investors. Earnings Call Transcript
• Negative Sentiment: EPS miss — Q1 EPS was $1.89, below consensus (about $1.97) and down from $2.54 a year earlier, a clear earnings disappointment that weighed on sentiment. Zacks
• Negative Sentiment: Guidance cut — Management trimmed its FY?2026 outlook, issuing revenue guidance of about $2.5B–$2.6B versus consensus nearer the top of that range; the company explicitly lowered its outlook, which is the main driver of the share decline. TipRanks

Bio-Rad Laboratories Trading Down 8.7%

Shares of BIO stock opened at $255.70 on Friday. The firm’s 50-day simple moving average is $277.81 and its 200-day simple moving average is $298.20. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.62 and a quick ratio of 4.19. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $343.12. The firm has a market cap of $6.90 billion, a P/E ratio of 9.16 and a beta of 1.06.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 EPS for the quarter, missing the consensus estimate of $1.97 by ($0.08). The company had revenue of $592.10 million for the quarter, compared to analyst estimates of $589.91 million. Bio-Rad Laboratories had a return on equity of 3.52% and a net margin of 6.52%.The business’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period last year, the company posted $2.54 EPS. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.32 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BIO. Wells Fargo & Company lowered their price target on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a report on Friday. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their price target for the company from $375.00 to $300.00 in a report on Tuesday, April 7th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $333.00.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.